In order to evaluate which genetic maker could have a greater influence on drug response, we compared IGHV unmuted/ATMWT group versus cases with ATM biallelic inactivation, showing that CLL patients with biallelic loss of ATM were more sensitive to the drug combination (Supplemental Fig. S6b). The gene discussed is ATM; the disease is B-cell chronic lymphocytic leukemia.